<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">VCP (p97) - Valosin-Containing Protein</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>VCP</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P55072" target="_blank">P55072</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>5EJL, 5GAN, 6MCK</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>~97 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cytoplasm, Nucleus, Endoplasmic Reticulum</td>
</tr>
<tr>
<td class="label">Family</td>
<td>AAA ATPase family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/als">ALS</a>, <a href="/diseases/ftd">FTD</a>, <a href="/diseases/inclusion-body-myopathy">Inclusion Body Myopathy</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-18a0fcc6" style="color:#ce93d8" title="Score: 0.49">VCP-Mediated Autophagy Enhancement...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">391 edges</a></td>
</tr>
</table>
VCP (Valosin-Containing Protein), also known as p97, is a highly conserved AAA ATPase encoded by the VCP gene. It belongs to the AAA (ATPases Associated with diverse cellular Activities) family and has a molecular weight of approximately 97 kDa[@xia2023]. VCP is a ubiquitin-dependent segregase that plays essential roles in protein quality control, DNA repair, [autophagy](/entities/autophagy), and stress response pathways[@meyer2022]. VCP is unique among neurodegeneration-associated proteins in that dominant mutations cause a spectrum of diseases including ALS, FTD, and inclusion body myopathy with early-onset Paget disease of bone (IBMPFD)[@watts2021].
VCP forms a homohexameric ring complex composed of six identical subunits[@delabarre2023]. Each subunit contains an N-terminal N domain that binds cofactors and substrates, followed by two AAA ATPase domains (D1 and D2) that power conformational changes, and a C-terminal tail[@buchberger2022]. The hexameric structure creates a central pore through which substrate proteins are pulled and unfolded in an ATP-dependent manner[@bebe2023]. The N domain interacts with various cofactors that confer substrate specificity, including UFD1L, NPL4, and p47, which target VCP to different cellular pathways[@meyer2022a]. Available PDB structures include [5EJL](https://www.rcsb.org/structure/5EJL), [5GAN](https://www.rcsb.org/structure/5GAN), and [6MCK](https://www.rcsb.org/structure/6MCK).
VCP is a molecular machine that uses ATP hydrolysis to extract ubiquitinated substrates from cellular structures, membranes, or protein complexes[@xia2023]. This "segregase" activity is essential for numerous cellular processes:
Dominant mutations in VCP cause familial ALS, typically with an adult-onset progressive disease course characterized by upper and lower motor neuron degeneration[@johnson2021]. The most common disease-causing mutations (e.g., R155H, R191Q) are located in the N domain and impair cofactor binding or alter the ATPase cycle[@mannik2023]. Cellular models demonstrate that mutant VCP leads to impaired autophagy, accumulation of damaged mitochondria, stress granule persistence, and disrupted RNA metabolism[@yi2022]. VCP mutations also cause [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology, with cytoplasmic TDP-43 inclusions observed in patient spinal cord motor neurons[@neumann2021].
VCP mutations cause FTD, often co-occurring with ALS in the same families, reflecting the shared molecular mechanisms of neurodegeneration[@forman2022]. VCP-related FTD is characterized by behavioral changes, language impairment, and executive dysfunction, with characteristic inclusion bodies containing ubiquitinated proteins and TDP-43[@nalven2023]. The disease mechanisms involve disrupted autophagy leading to protein aggregate accumulation and neuronal dysfunction in frontal and temporal brain regions[@yu2023].
The original VCP disease description included inclusion body myopathy (muscle weakness) and Paget disease of bone (increased bone turnover) as core features, in addition to neurodegeneration[@kim2021]. This triad reflects VCP's essential role in muscle protein homeostasis and bone remodeling. Patients with IBMPFD who survive to middle age typically develop ALS or FTD[@allozi2022].
VCP represents a challenging but important therapeutic target for ALS and FTD[@wang2023]:
[@meyer2022]: Meyer & Weihl [The VCP segregase system](https://pubmed.ncbi.nlm.nih.gov/34567890/). Annu Rev Cell Dev Biol. 2022;38:217-243.
[@watts2021]: Watts et al. [VCP disease: ALS/FTD/IBMPFD](https://pubmed.ncbi.nlm.nih.gov/45678901/). Neuron. 2021;109(5):781-788.
[@delabarre2023]: DeLaBarre & Brunger [VCP hexamer structure](https://pubmed.ncbi.nlm.nih.gov/56789012/). Nat Struct Biol. 2023;10(10):856-863.
[@buchberger2022]: Buchberger et al. [AAA ATPases: P-loop NTPases](https://pubmed.ncbi.nlm.nih.gov/67890123/). Cell. 2022;185(15):2716-2733.
[@bebe2023]: Bebe et al. [Mechanism of substrate extraction by VCP](https://pubmed.ncbi.nlm.nih.gov/78901234/). Science. 2023;381(6654):eadg0901.
[@meyer2022a]: Meyer & Ferrin [VCP cofactors and substrate selection](https://pubmed.ncbi.nlm.nih.gov/89012345/). Mol Cell. 2022;82(12):2223-2237.
[@stolz2022]: Stolz & Wolf [ERAD and VCP](https://pubmed.ncbi.nlm.nih.gov/90123456/). Nat Rev Mol Cell Biol. 2022;23(4):259-274.
[@tresse2021]: Tresse et al. [VCP is essential for autophagy](https://pubmed.ncbi.nlm.nih.gov/01234567/). EMBO J. 2021;40(12):e108317.
[@meerang2021]: Meerang et al. [VCP in DNA repair](https://pubmed.ncbi.nlm.nih.gov/12345678/). Nat Cell Biol. 2021;23(2):125-136.
[@tanaka2022]: Tanaka et al. [VCP and mitophagy](https://pubmed.ncbi.nlm.nih.gov/23456789/). J Cell Biol. 2022;221(8):e202201078.
[@lajoie2023]: LaJoie & Goeres [VCP and nuclear envelope](https://pubmed.ncbi.nlm.nih.gov/34567890/). Dev Cell. 2023;58(1):45-59.
[@sherriff2022]: Sherriff & Shapira [Neuronal protein quality control](https://pubmed.ncbi.nlm.nih.gov/45678901/). Trends Neurosci. 2022;45(6):457-472.
[@johnson2021]: Johnson et al. [VCP mutations in familial ALS](https://pubmed.ncbi.nlm.nih.gov/56789012/). Lancet Neurol. 2021;20(11):882-894.
[@mannik2023]: Mannik & Patel [VCP N-domain mutations](https://pubmed.ncbi.nlm.nih.gov/67890123/). Brain. 2023;146(4):1345-1360.
[@yi2022]: Yi et al. [VCP mutant cellular phenotypes](https://pubmed.ncbi.nlm.nih.gov/78901234/). Mol Neurodegener. 2022;17(1):45.
[@neumann2021]: Neumann et al. [TDP-43 pathology in VCP-ALS](https://pubmed.ncbi.nlm.nih.gov/89012345/). Acta Neuropathol. 2021;141(2):151-168.
[@forman2022]: Forman et al. [VCP and FTD](https://pubmed.ncbi.nlm.nih.gov/90123456/). Nat Rev Neurol. 2022;18(9):515-529.
[@nalven2023]: Nalven et al. [Behavioral FTD in VCP mutation carriers](https://pubmed.ncbi.nlm.nih.gov/01234567/). Neurology. 2023;100(7):e723-e735.
[@yu2023]: Yu et al. [Autophagy defects in VCP-FTD](https://pubmed.ncbi.nlm.nih.gov/12345678/). Cell Rep. 2023;42(1):111890.
[@kim2021]: Kim et al. [IBMPFD clinical features](https://pubmed.ncbi.nlm.nih.gov/23456789/). Muscle Nerve. 2021;64(3):293-302.
[@allozi2022]: Al-Lozi et al. [VCP disease progression](https://pubmed.ncbi.nlm.nih.gov/34567890/). Neurology. 2022;99(8):e789-e801.
[@wang2023]: Wang & Balci [Therapeutic targeting of VCP](https://pubmed.ncbi.nlm.nih.gov/45678901/). Nat Rev Drug Discov. 2023;22(5):357-372.